A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

• Status: Completed
• Trial end date: 2016-07-18
• Target enrollment: 0
• Participant gender: Male

Summary

This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edwin Posadas, MD

Criteria

KEY INCLUSION CRITERIA

• mCRPC that includes visceral disease. Visceral metastatic disease is defined as solid organ infiltration that is not bone or lymph node metastases.

KEY EXCLUSION CRITERIA

• Recent history (<6 months) of gastrointestinal hemorrhage requiring blood transfusion.

• Tumor involvement in the intestinal lining which the treating physician deems at risk for perforation with rapid tumor response.